Pharmacoeconomic Guidelines Unclear On Dealing With Patient Differences

Published May 17, 2013
Maastricht, The Netherlands - Acknowledging patient heterogeneity in economic evaluations and subsequent reimbursement decisions may lead to more effective and/or efficient health care. Despite this potential gain, patient heterogeneity is still frequently neglected in economic evaluations. National pharmacoeconomic guidelines, which provide guidance on performing economic evaluations, should stimulate and facilitate the acknowledgement of patient heterogeneity by providing specific guidance on acknowledging patient heterogeneity. The checklist presented in the paper, “How Should We Deal with Patient Heterogeneity in Economic Evaluation: A Systematic Review of National Pharmacoeconomic Guidelines,” published in Value in Health, can assist in formulating this guidance. Bram Ramaekers, Manuela Joore (both from Maastricht University Medical Centre) and Janneke Grutters (Radboud University Nijmegen Medical Centre) systematically reviewed and analyzed recommendations from national pharmacoeconomic guidelines with regard to acknowledging patient heterogeneity in economic evaluations. They found that the majority of national pharmacoeconomic guidelines provide general guidance on acknowledging patient heterogeneity in economic evaluations. However, its usefulness is limited since this guidance is mostly not specific. “Acknowledging patient heterogeneity is considered as part of quality criteria for good practice in economic evaluations and general guidance on this topic is presented in most pharmacoeconomic guidelines. Thus, it seems that the importance of acknowledging patient heterogeneity is internationally recognized, while there is a lack of consensus on specific recommendations to acknowledge patient heterogeneity in economic evaluations.” states Bram Ramaekers. “Therefore, we advise the further development of pharmacoeconomic guidelines to provide specific guidance on acknowledging patient heterogeneity. This could facilitate the systematic and transparent handling of patient heterogeneity in economic evaluations worldwide.”

Value in Health (ISSN 1098-3015) publishes papers, concepts, and ideas that advance the field of pharmacoeconomics and outcomes research as well as policy papers to help health care leaders make evidence-based decisions. The journal is published bi-monthly and has over 8,000 subscribers (clinicians, decision makers, and researchers worldwide).

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is a nonprofit, international, educational and scientific organization that strives to increase the efficiency, effectiveness, and fairness of health care resource use to improve health.

For more information: www.ispor.org

Related Stories

ISPOR Task Force Addresses Critical Gap in Surrogate Endpoint Guidance

May 28, 2026

Value in Health, announced the publication of an ISPOR Good Practices Report providing guidance on the use of surrogate endpoint evaluation methods in health technology assessment (HTA) decision making. The report, “Methods for Evaluation of Surrogate Endpoints for HTA Decision Making: A Good Practices Report of an ISPOR Task Force,” was published in the May 2026 issue of Value in Health.

How Is Health Valued in the United Kingdom? We Finally Have a Better Answer

May 27, 2026

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced today the publication of a pair of companion articles that together establish both the methodological foundation of the first definitive UK value set for the EQ-5D-5L and the practical implications of adopting it—thus equipping health technology assessment decision makers with a UK value set suitable for informing policy. The articles were featured in the May 2026 issue of Value in Health.

From Promise to Proof: Strengthening the Evidence Base for Digital Health Technologies

Apr 28, 2026

Value in Health announced the publication of a special themed section of research papers that advances evidence and methods for evaluating the real-world value of digital health technologies.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×